Solid guns for Sarepta
Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.
Combination trial could be start of second act for Amgen’s Imlygic
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.
FDA panel to act on Impulse
An adcom for Impulse Dynamics’ heart muscle stimulator is approaching, and the group will want to avoid a nasty shock.
Keytruda’s chance to take on Tecentriq in breast cancer
Upcoming readout of the Keynote-522 trial could open up the neoadjuvant triple-negative breast cancer setting for the Merck & Co drug.
SITC event – Nektar hopes to pivot away from Incyte's failure
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Event – Genkyotex gets a second chance
Genkyotex hopes for a reboot with upcoming data on its previously failed lead project, GKT831, in primary biliary cirrhosis.
Portico has its foot in the door, but various trials await
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
Novartis nears gene therapy confirmation
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
Trulicity’s turn to show a cardiovascular benefit
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.